Back to results
US 8,853,408 B2Granted
Cyclopropylamines as LSD1 inhibitors
AssigneeGlaxoSmithKline Intellectual Property (No. 2) Limited
InventorsNeil W. Johnson, Jiri Kasparec
Life of this patent
Estimating the term…
Abstract
This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
Claims4
A compound which is 4-((4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid, represented by the formula:
- or a pharmaceutically acceptable salt thereof.
A compound which is 4-((4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid, represented by the formula:
Dependencies are inferred from the claim text.